Twist Bioscience manufactures synthetic DNA and related products using a silicon-based high-throughput synthesis platform. Its offering includes custom genes, oligo pools, NGS tools and antibody discovery services for biotech, pharma and research customers. The chip-based approach aims to make writing DNA faster, denser and more cost-efficient than traditional methods, supporting synthetic biology and genomics workflows.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 96.1 | — | 20.4 | — |
| Q3 2025 | 99 | — | -27.1 | — |
| Q4 2025 | 103.7 | — | -30.5 | — |
| Q1 2026 | 110.7 | — | -44 | — |
| Q2 2026 | 118.4 | 23.2% | -35 | -271.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: GitLab Inc. (GTLB), Liberty Live Holdings, Inc. (LLYVA), Kymera Therapeutics, Inc. (KYMR), Caris Life Sciences, Inc. (CAI), Cytokinetics, Incorporated (CYTK), Chord Energy Corporation (CHRD)